Blue Cap is set to benefit from recent potentially transformative deals. The projected turnaround of Neschen may yield a step-change in profit, while the disposal of Biolink on a chemical industry-leading multiple confirms the success of management’s exit strategy. Otherwise, a strong, coherent business model is evident in a solid financial record and outlook. Indeed, current consensus forecasts appear not to reflect adequately the general improvement in trading and this virtual de-gearing; adjusted 2017e EV/EBITDA of under 7x ignores the proven corporate success and increasingly ambitious investment.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs